The 2 Minute Medicine® Podcast- FDA Approvals, Transplant Breakthroughs, Gene Therapy Manufacturing, and ADC Safety Signals

This Pharma Roundup episode reviews four major regulatory and clinical developments shaping early 2026. It begins with the Food and Drug Administration approval of Nuzolvence (zoliflodacin), a first-in-class oral antibiotic for uncomplicated gonorrhea offering a needle-free alternative amid rising antimicrobial resistance. The episode then covers the approval of Yartemlea for hematopoietic stem cell transplant–associated thrombotic microangiopathy, signaling a shift toward disease-modifying therapy. It also examines the FDA’s new risk-based flexibility in Chemistry, Manufacturing, and Controls requirements for cell and gene therapies. The episode concludes with a discussion of the partial clinical hold on ifinatamab deruxtecan following safety concerns related to interstitial lung disease.